Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $124
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Jayson Bedford has maintained an Outperform rating on Abbott Laboratories (NYSE:ABT) and increased the price target from $110 to $124.
January 03, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Jayson Bedford reaffirmed an Outperform rating on Abbott Laboratories and raised the price target to $124, indicating a positive outlook on the stock.
The increase in price target by Raymond James reflects a bullish sentiment on Abbott Laboratories, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100